First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study
- Sponsor
- King Faisal Specialist Hospital & Research Center
- Study ID
- NCT00537901
- Status
- Completed
Conditions
- Colonic Neoplasms
- Rectal Neoplasms
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- First-Line Bevacizumab and Chemotherapy — RADIATIONChemotherapy
- Bevacizumab — DRUGChemotherapy
Study Details
First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum
Key Dates
- First listed
- Oct 2, 2007
- Start date
- Oct 31, 2007
- Status verified
- Dec 2015
- Primary completion
- Oct 31, 2013
- Completion
- Oct 31, 2013
Study Design
- Enrollment
- 100 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Effectiveness [ Time Frame: overall ]
Related Studies
- Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and AdenomasRecruiting · University of Michigan Rogel Cancer Center · Los Angeles, California
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyRecruiting · UMC Utrecht · Pittsburgh, Pennsylvania
- Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon CancerRecruiting · AdventHealth Translational Research Institute · Oakland, California
- Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal CancerRecruiting · AdventHealth Translational Research Institute · Orlando, Florida